Dual role of glycans and binding receptors in pathogenesis of enveloped viruses (by mainly focusing on two recent pandemics).

A period of about a decade has been estimated to pass for the emergence of a new infectious strain of a virus that may lead to the occurrence of a pandemic one. It is now suggested that the variants of the 1918 H1N1 and coronavirus disease-19 pandemics could have existed in humans after the initial cross-species introduction to humans and underwent multiple low-level seasonal epidemics before the occurrence of their outbreaks. They share similarities in the continuation, widespreadness due to high transmissibility, high fatality rate and clinical symptoms. They are assumed to share a similar principle of a zoonotic source and a cross-species pathway for transmission. They show some similarities in their pathogenesis with other enveloped viruses: Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), human immunodeficiency virus, Ebola, Lassa and measles viruses. The highly pathogenic nature of these viruses and their genetic variants may depend on their binding affinity for host cell receptors, whereby they efficiently circumvent or block host cell immune responses triggered by cytokines (interferon). High transmission rates and viral pathogenicity are attributed to glycan moieties that facilitate virus binding to host multiple receptors and cell entry, thereby helping viruses to evade immune recognition and response. Also, mucosa glycotopes are a matter of concern that play as primary sites for virus attachment and body entry. Finding general lectins or ligands that block the viral-host receptors interaction or identifying individual glycotopes is the therapeutic and prognosis topic that demands the main focus.

Enveloped Viruses: Pathogenetic Targets for Cyanobacterial Lectins.

Lectins are a group of highly specific carbohydrate-binding proteins with a wide spectrum of action, involved in the so-called <<first line>> of body defense. These unique biomolecules show high specificity for various mono- and oligosaccharides, primarily for viral and bacterial glycoconjugates. Cyanobacteria lectins are effective against enveloped viruses and are an appealing alternative to existing synthetic drugs. Virtually complete absence of resistance formation in viruses to these compounds is known. The purpose of this review is to analyze, summarize, and discuss the results of experimental studies in vivo and in vitro, illustrating the mechanisms of action and antiviral effects of lectins obtained from cyanobacteria in relation to the most dangerous and socially significant viruses: SARS-Cov-2, HIV, Ebola viruses, influenza, and hepatitis C. In addition, the article outlines some of the challenges that must be overcome in order to obtain effective antiviral drugs in the future.Copyright © Team of Authors, 2022.

Enveloped Viruses: Pathogenetic Targets for Cyanobacterial Lectins.

Lectins are a group of highly specific carbohydrate-binding proteins with a wide spectrum of action, involved in the so-called <<first line>> of body defense. These unique biomolecules show high specificity for various mono- and oligosaccharides, primarily for viral and bacterial glycoconjugates. Cyanobacteria lectins are effective against enveloped viruses and are an appealing alternative to existing synthetic drugs. Virtually complete absence of resistance formation in viruses to these compounds is known. The purpose of this review is to analyze, summarize, and discuss the results of experimental studies in vivo and in vitro, illustrating the mechanisms of action and antiviral effects of lectins obtained from cyanobacteria in relation to the most dangerous and socially significant viruses: SARS-Cov-2, HIV, Ebola viruses, influenza, and hepatitis C. In addition, the article outlines some of the challenges that must be overcome in order to obtain effective antiviral drugs in the future.Copyright © Team of Authors, 2022.

Lectins and polysaccharides against SARS-CoV-2

Proteins with hemagglutination properties that were later demonstrated to be sugar-specific and eventually termed lectins have been found in nature but they sparked little interest until around two decades ago. Lectins are naturally occurring bioactive proteins and glycoproteins that have the potential to bind glycans found on viruses' envelope glycoproteins or viral surface glycans, inhibiting virus penetration into host cells and transmission. The infectious virion particles of SARS-CoV-2 are surrounded by a lipoprotein envelope generated from the host cell during budding. The envelope glycoproteins of SARS-CoV-2, like those of other enveloped viruses, play a role in viral adherence and entrance. In SARS, coronavirus is susceptible to mannose-specific lectins. These lectins inhibit viral development by interfering with viral attachment during the early stages of the replication cycle. Similarly, certain sulfated polysaccharides bind firmly to the heparan sulfate co-receptor in host tissues and interfere with the S-protein of SARS-CoV-2 (in vitro), thus inhibiting the COVID-19 infection. Lectins and polysaccharides might be considered leading compounds for developing novel antiviral strategies owing to their capacity to block viral entrance and replication in the host cell. Lectin-carbohydrate interactions can also be utilized to create diagnostic devices that target viral glycoproteins or host glycoprotein changes during viral infections, allowing for quick, accurate, and cost-effective detection of infected people. Altogether, the data compiled in this chapter highlights the importance of lectins and polysaccharides against SARS-CoV-2 to provide potential solutions for emerging complex aspects of different health challenges. © 2023 Elsevier Inc. All rights reserved.

Anti-coronaviral Activity of Plant and Seaweed Secondary Metabolites: A Review

Background: Coronavirus Disease 2019 (COVID-19), one of the greatest challenges facing humanity, continues to affect millions of people worldwide. Vaccines approved and authorized for use are effective against COVID-19, but viral variants of concern may emerge in the near future. The discovery of novel antiviral agents will help humanity overcome COVID-19 and aid in any future viral pandemics. Objective(s): This review aimed to evaluate evidence from the plant-and seaweed-derived secondary com-pound-based interventions for viral diseases caused by coronaviruses. Method(s): A comprehensive search of several databases, including Cochrane Library, Web of Science and PubMed was conducted to identify available studies evaluating the outcomes of plant-and seaweed secondary metabolites in viral diseases such as Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome and COVID-19. Result(s): The volume of existing reports is irrefutable evidence that some plant-and seaweed-derived secondary compounds (e.g., mannose-specific lectins, griffithsin, cyanovirin-N, gallate, curcumin, luteo-lin, quercetin and betulinic acid) possess a potential antiviral ability against coronaviruses, including SARS-CoV-2. Conclusion(s): Plant and seaweed secondary metabolites with antiviral activity show their activity in different metabolic pathways. Besides reducing and preventing the metabolic damage caused by proinflamma-tory cytokines and oxidative stress, several plants and seaweed secondary metabolites can also be effective in improving some clinical indexes specific to COVID-19. Despite their effectiveness in preclinical studies, plant and seaweed-derived secondary compounds need more pharmacokinetic studies and safety measures concerning their mitogenic and allergenic properties.Copyright © 2022 Bentham Science Publishers.

A new approach for extracting information from protein dynamics.

Increased ability to predict protein structures is moving research focus towards understanding protein dynamics. A promising approach is to represent protein dynamics through networks and take advantage of well-developed methods from network science. Most studies build protein dynamics networks from correlation measures, an approach that only works under very specific conditions, instead of the more robust inverse approach. Thus, we apply the inverse approach to the dynamics of protein dihedral angles, a system of internal coordinates, to avoid structural alignment. Using the well-characterized adhesion protein, FimH, we show that our method identifies networks that are physically interpretable, robust, and relevant to the allosteric pathway sites. We further use our approach to detect dynamical differences, despite structural similarity, for Siglec-8 in the immune system, and the SARS-CoV-2 spike protein. Our study demonstrates that using the inverse approach to extract a network from protein dynamics yields important biophysical insights.

Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.

SARS-CoV-2 remains a global health crisis even with effective vaccines and the availability of FDA approved therapies. Efforts to understand the complex disease pathology and develop effective strategies to limit mortality and morbidity are needed. Recent studies reveal circulating Galectin-9 (gal-9), a soluble beta-galactoside binding lectin with immunoregulatory properties, are elevated in SARS-CoV-2 infected individuals with moderate to severe disease. Moreover, in silico studies demonstrate gal-9 can potentially competitively bind the ACE2 receptor on susceptible host cells. Here, we determined whether early introduction of exogenous gal-9 following SARS-CoV-2 infection in humanized ACE2 transgenic mice (K18-hACE2) may reduce disease severity. Mice were infected and treated with a single dose of a human recombinant form of gal-9 (rh-gal-9) and monitored for morbidity. Subgroups of mice were humanely euthanized at 2- and 5- days post infection (dpi) for viral levels by plaque assay, immune changes measures by flow cytometry, and soluble mediators by protein analysis from lung tissue and bronchoalveolar Lavage fluid (BALF). Mice treated with rh-gal-9 during acute infection had improved survival compared to PBS treated controls. At 5 dpi, rh-gal-9 treated mice had enhanced viral clearance in the BALF, but not in the lung parenchyma. Increased T and dendritic cells and decreased neutrophil frequencies in the lung at 5 dpi were observed, whereas BALF had elevated levels of type-I interferons and proinflammatory cytokines. These results suggest a role for rh-gal-9 in limiting acute COVID-19. Further studies are required to determine the optimal design of gal-9 treatment to effectively ameliorate COVID-19 disease.

Immunostimulant plant proteins: Potential candidates as vaccine adjuvants.

The COVID-19 pandemic is shaking up global scientific structures toward addressing antibiotic resistance threats and indicates an urgent need to develop more cost-effective vaccines. Vaccine adjuvants play a crucial role in boosting immunogenicity and improving vaccine efficacy. The toxicity and adversity of most adjuvant formulations are the major human immunization problems, especially in routine pediatric and immunocompromised patients. The present review focused on preclinical studies of immunoadjuvant plant proteins in use with antiparasitic, antifungal, and antiviral vaccines. Moreover, this report outlines the current perspective of immunostimulant plant protein candidates that can be used by researchers in developing new generations of vaccine-adjuvants. Future clinical studies are required to substantiate the plant proteins' safety and applicability as a vaccine adjuvant in pharmaceutical manufacturing.

Lectin Analysis of SARS-CoV-2-Positive Nasopharyngeal Samples Using GLYcoPROFILE® Technology Platform.

Nasopharyngeal samples are currently accepted as the standard diagnostic samples for nucleic acid amplification testing and antigenic testing for the SARS-CoV-2 virus. In addition to the diagnostic capacity of SARS-CoV-2-positive crude nasopharyngeal samples, their qualitative potential for direct glycan-specific analysis, in order to uncover unique glycol profiles, was assessed. In this study we provide glycan characterization of SARS-CoV-2-positive and -negative nasopharyngeal samples directly from lectin interactions. Although with limited throughput, this study evaluated the clinical sensitivity and specificity of the GLYcoPROFILE® technology platformon45crude nasopharyngeal samples collected between November 2020 and April 2022. Each GLYcoPROFILE® of 39 SARS-CoV-2-positive samples was compared toglycoprofiling on a panel of 10 selected lectins and the results were paralleled with SARS-CoV-2-negative samples' results. The GLYcoPROFILE® showed a clear distinction between positive and negative samples with WFA, GSL-II, PHA-L (GlcNAc-specific) and BPA (GalNAc-specific) highlighted as relevant lectins in SARS-CoV-2-positive samples. In addition, a significant, positive statistical correlation was found for these lectins (p < 0.01).

Chapter 10 - Lectins and polysaccharides against SARS-CoV-2

Proteins with hemagglutination properties that were later demonstrated to be sugar-specific and eventually termed lectins have been found in nature but they sparked little interest until around two decades ago. Lectins are naturally occurring bioactive proteins and glycoproteins that have the potential to bind glycans found on viruses’ envelope glycoproteins or viral surface glycans, inhibiting virus penetration into host cells and transmission. The infectious virion particles of SARS-CoV-2 are surrounded by a lipoprotein envelope generated from the host cell during budding. The envelope glycoproteins of SARS-CoV-2, like those of other enveloped viruses, play a role in viral adherence and entrance. In SARS, coronavirus is susceptible to mannose-specific lectins. These lectins inhibit viral development by interfering with viral attachment during the early stages of the replication cycle. Similarly, certain sulfated polysaccharides bind firmly to the heparan sulfate co-receptor in host tissues and interfere with the S-protein of SARS-CoV-2 (in vitro), thus inhibiting the COVID-19 infection. Lectins and polysaccharides might be considered leading compounds for developing novel antiviral strategies owing to their capacity to block viral entrance and replication in the host cell. Lectin-carbohydrate interactions can also be utilized to create diagnostic devices that target viral glycoproteins or host glycoprotein changes during viral infections, allowing for quick, accurate, and cost-effective detection of infected people. Altogether, the data compiled in this chapter highlights the importance of lectins and polysaccharides against SARS-CoV-2 to provide potential solutions for emerging complex aspects of different health challenges.

Plant Lectins: A Review On Their Biotechnological Potential Toward Human Pathogens.

The indiscriminate use of antibiotics is associated with the appearance of bacterial resistance. In light of this, plant-based products treating infections are considered potential alternatives. Lectins are a group of proteins widely distributed in nature, capable of reversibly binding carbohydrates. Lectins can bind to the surface of pathogens and cause damage to their structure, thus preventing host infection. The antimicrobial activity of plant lectins results from their interaction with carbohydrates present in the bacterial cell wall and fungal membrane. The data about lectins as modulating agents of antibiotic activity, potentiates the effect of antibiotics without triggering microbial resistance. In addition, lectins play an essential role in the defense against fungi, reducing their infectivity and pathogenicity. Little is known about the antiviral activity of plant lectins. However, their effectiveness against retroviruses and parainfluenza is reported in the literature. Some authors still consider mannose/glucose/N-Acetylglucosamine binding lectins as potent antiviral agents against coronavirus, suggesting that these lectins may have inhibitory activity against SARS-CoV-2. Thus, it was found that plant lectins are an alternative for producing new antimicrobial drugs, but further studies still need to decipher some mechanisms of action.

An Update of Lectins from Marine Organisms: Characterization, Extraction Methodology, and Potential Biofunctional Applications.

Lectins are a unique group of nonimmune carbohydrate-binding proteins or glycoproteins that exhibit specific and reversible carbohydrate-binding activity in a non-catalytic manner. Lectins have diverse sources and are classified according to their origins, such as plant lectins, animal lectins, and fish lectins. Marine organisms including fish, crustaceans, and mollusks produce a myriad of lectins, including rhamnose binding lectins (RBL), fucose-binding lectins (FTL), mannose-binding lectin, galectins, galactose binding lectins, and C-type lectins. The widely used method of extracting lectins from marine samples is a simple two-step process employing a polar salt solution and purification by column chromatography. Lectins exert several immunomodulatory functions, including pathogen recognition, inflammatory reactions, participating in various hemocyte functions (e.g., agglutination), phagocytic reactions, among others. Lectins can also control cell proliferation, protein folding, RNA splicing, and trafficking of molecules. Due to their reported biological and pharmaceutical activities, lectins have attracted the attention of scientists and industries (i.e., food, biomedical, and pharmaceutical industries). Therefore, this review aims to update current information on lectins from marine organisms, their characterization, extraction, and biofunctionalities.

Glycoinformatics approach for identifying target positions to inhibit initial binding of SARS-CoV-2 S1 protein to the host cell

COVID-19 outbreak is still threatening the public health. Therefore, in the middle of the pandemic, all kind of knowledge on SARS-CoV-2 may help us to find the solution. Determining the 3D structures of the proteins involved in host-pathogen interactions are of great importance in the fight against infection. Besides, post-translational modifications of the protein on 3D structure should be revealed in order to understand the protein function since these modifications are responsible for the host-pathogen interaction. Based on these, we predicted O-glycosylation and phosphorylation positions using full amino acid sequence of S1 protein. Candidate positions were further analyzed with enzyme binding activity, solvent accessibility, surface area parameters and the positions determined with high accuracy rate were used to design 3D O-glycoprotein structure of the S1 protein using carbohydrate force field. In addition, the interaction between the C-type lectin CD209L and a-mannose residues was examined and carbohydrate recognition positions were predicted. We suggest these positions as a potential target for the inhibition of the initial binding of SARS-CoV-2 S1 protein to the host cell.

Therapeutic potential of targeting galectins - A biomaterials-focused perspective.

Among all the biological entities involved in the immune response, galectins, a family of glycan-binding proteins, have been described as key in immune cell homeostasis and modulation. More importantly, only some galectin family members are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. As they are expressed in most major diseases, their potential as targets for new therapies seems promising. Most of the galectin family members' ubiquitous expression points to the need for targeted treatments to ensure effectiveness. Engineered biomaterials are emerging as a promising method to improve galectin-targeted strategies' therapeutic performance. In this review, we provide an overview of the role of galectins in health and disease and their potential as therapeutic targets, as well as the state-of-the-art and future directions of galectin-targeted biomaterials.

A look at the C3 and C5 proteins in the Covid‐19

Because of the crucial role played by proteins C3 and C5 in the infection by the SARS-COV-2 virus, new complement system inhibition treatments have emerged as a possible first line of defense against the worst symptoms developed during Covid-19 disease. C3, C5, Complemento, Inhibición, SARS-CoV-2 INTRODUCTION In December 2019, China informed the World Health Organization (WHO) about the spread of a new pathogen in the Chinese city of Wuhan, this pathogen was named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Abd El-Aziz and Stockand, 2020), causing the Covid-19 disease. Once a person is infected with the SARSCoV-2 virus, the spike homotrimer glycoprotein of the virus connects to the integral membrane protein ACE2 of human cells (Lan et al., 2020;Rothan and Byrareddy, 2020), many of these receptors are found in the lung epithelium layer, making them one of the main sites of infection of the SARS-CoV-2 virus (Connors and Levy, 2020). The activation of the complement system is vital to the control of viruses, fungi, bacteria, and other pathogens, this activation triggers the opsonization of the pathogens and the elimination of them (Merle et al., 2015;Sarma and Ward, 2011);the activation is sequential: a catalytic cascade is produced through the generation of complex enzymes and proteins, in one step an enzyme or protein of this cascade can generate many active molecules for the next step in the activation of the complement system (Merle et al., 2015).

Lectins and lectibodies: potential promising antiviral agents.

In nature, lectins are widely dispersed proteins that selectively recognize and bind to carbohydrates and glycoconjugates via reversible bonds at specific binding sites. Many viral diseases have been treated with lectins due to their wide range of structures, specificity for carbohydrates, and ability to bind carbohydrates. Through hemagglutination assays, these proteins can be detected interacting with various carbohydrates on the surface of cells and viral envelopes. This review discusses the most robust lectins and their rationally engineered versions, such as lectibodies, as antiviral proteins. Fusion of lectin and antibody's crystallizable fragment (Fc) of immunoglobulin G (IgG) produces a molecule called a "lectibody" that can act as a carbohydrate-targeting antibody. Lectibodies can not only bind to the surface glycoproteins via their lectins and neutralize and clear viruses or infected cells by viruses but also perform Fc-mediated antibody effector functions. These functions include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cell-mediated phagocytosis (ADCP). In addition to entering host cells, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein S1 binds to angiotensin-converting enzyme 2 (ACE2) and downregulates it and type I interferons in a way that may lead to lung disease. The SARS-CoV-2 spike protein S1 and human immunodeficiency virus (HIV) envelope are heavily glycosylated, which could make them a major target for developing vaccines, diagnostic tests, and therapeutic drugs. Lectibodies can lead to neutralization and clearance of viruses and cells infected by viruses by binding to glycans located on the envelope surface (e.g., the heavily glycosylated SARS-CoV-2 spike protein).

Peruvian plants of traditional use as potential sources of molecules with activity against COVID-19

Introduction: The current situation of COVID-19 is a big issue for the human population. At present, no healing drug is available in the market. Researchers are doing their best to produce drugs to fight the disease. Various efforts are being considered based on different directions of scientific knowledge and technologies for the treatment of the disease. Unfortunately, none of these drugs works absolutely against the pandemic. Therefore, bioactive molecules from plants, animals and microorganisms could be a better option to treat COVID-19. Objective: Review the literature about species of the flora of Peru used for the treatment of respiratory diseases and highlight the plants with potential in the production of secondary metabolites and plant lectins as an alternative against COVID-19. Methods: A review was conducted of scientific articles related to the use of traditional medicine in Peru, China, and India for the treatment of respiratory diseases, as well as information about plant lectins and secondary metabolites potentially useful against COVID-19. Results: A long list is presented of genera and species of the flora of Peru with great potential against COVID-19. Most of these species belong to the Asteraceae, Loranthaceae, Piperaceae, Viscaceae and Zingiberaceae families. Numerous species are endemic to Peru. Conclusions: The flora of Peru has more than 22 000 plant species. Many of these species are traditionally used in the treatment of respiratory diseases and are potentially useful for the treatment of COVID-19. © 2021, Editorial Ciencias Medicas. All rights reserved.

Plant lectins as potent Anti-coronaviruses, Anti-inflammatory, antinociceptive and antiulcer agents.

Lectins are defined as carbohydrate-binding proteins/glycoproteins of none immune origin, they are ubiquitous in nature, exist from bacteria to human cells. And due to their carbohydrate-binding recognition capacity, they have been a useful biological tool for the purification of glycoproteins and their subsequent characterization. Some plant lectins have also been revealed to own antinociceptive, antiulcer, and anti-inflammatory properties, where these features, in many instances, depending on the lectin carbohydrate-binding site. Coronavirus disease of 2019 (COVID-19) is a respiratory disease that struck the entire world leaving millions of people dead and more infected. Although COVID-19 vaccines have been made available, and quite a large number of world populations have already been immunized, the viral infection rates remained in acceleration, which continues to provoke major concern about the vaccines' efficacy. The belief in the ineffectiveness of the vaccine has been attributed in part to the recurrent mutations that occur in the epitope determinant fragments of the virus. Coronavirus envelope surface is extensively glycosylated being covered by more than sixty N-linked oligomannose, composite, and hybrid glycans with a core of Man3GlcNAc2Asn. In addition some O-linked glycans are also detected. Of these glyco-chains, many have also been exposed to several mutations, and a few remained conserved. Therefore, numerous plant lectins with a specificity directed towards these viral envelope sugars have been found to interact preferentially with them and are suggested to be scrutinized as a possible future tool to combat coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through blocking the viral attachment to the host cells. In this review, we will discuss the possible applications of plant lectins as anti-coronaviruses including SARS-CoV-2, antinociceptive, anti-inflammatory, and antiulcer agents with the proposed mechanism of their actions.

Lectins Are the Sparkle of Hope for Combating Coronaviruses and the Global COVID-19.

Today the crisis of coronavirus disease 2019 (COVID-19) pandemic represents a threatworldwide because it is a leading cause of human morbidity and mortality. Besides, it possessesa destroying impact on countries' economies. Therefore, there is an urgent need for hardresearch work and global collaboration to find a potential therapy. In this review, structuralgenomic variations in COVID-19 and further therapeutic options of Coronaviridae family orCOVID-19 are expressed. Lectins are natural proteins, which can exist in algae, higher plants,banana, actinomycetes, fungi, and archaea, and they have antiviral properties. Griffithsin lectin,isolated from red algae, has noteworthy efficacy against lethal SARS-CoV infection, humancoronaviruses, and other animal coronaviruses. Furthermore, all mannose-specific plant lectinshave anti-coronaviruses properties except for garlic lectins. However, lectins from mushroomscan act as immunomodulators by activating T-lymphocyte or stimulating dendrites or cytokines.The lectin may hinder glucans on viral spike protein and prevent entry and the virus's release.Lectin's anti-coronavirus activities include a glimmer of hope to tackle the global COVID-19crisis and inspire more scientific work on carbohydrate-binding agents against SARS-CoV-2.

Antiviral properties of microalgae and cyanobacteria

The recent outbreak of Corona Virus Disease (COVID-19) and the surge in accelerating the development of a vaccine to fight against the SARS-CoV-2 virus has imposed greater challenges to humanity worldwide. There is lack of research into the production of effective vaccines and methods of treatment against viral infections. As of now, strategies encompassing antiviral drugs and corticosteroids alongside mechanical respiratory treatment are in practice as frontline treatments. Though studies have reported that microalgae possess antiviral properties, only a few cases have presented the existence of antiviral compounds such as algal polysaccharides, lectins, aggluttinins, scytovirin, algal lipids such as sulfoquinovosyldiacylglycerol (SQDG), monogalactosyldiacylglycerides (MGDG) and digalactosyldiacylglycerides (DGDG), and algal biopigments especially chlorophyll analogues, marennine, phycobiliproteins, phycocyanin, phycoerythrin and allophycocyanin that are derived from marine and freshwater microalgae. Given the chemodiversity of bioactive compounds from microalgae and the present scenario, algal biotechnology is seen as a prospective source of antiviral and anti-inflammatory compounds that can be used to develop antiviral agents. Microalgae with potential as antivirals and microalgae derived functional compounds to treat viral diseases are summarized and can be used as a reference in developing algae-derived antivirals to treat SARS-CoV-2 and other similar viruses.